An international life sciences recruitment firm has seen an increase in contract placements by 250 per cent year on year with a substantial increase in demand for roles across the pharmaceutical industry.
Concilium Search revealed life sciences contracts, which involves securing individuals and teams for interim positions or project-based roles, is now the largest division within the business.
The company, which has offices in London, New York and Amsterdam has dealt with the increase in demand for contractors by pharma organisations by doubling the size of its life sciences recruitment contract team.
The Concilium Search figures were based on the firm experiencing an increase of 250 per cent in life sciences recruitment in the first six months of this year compared to 2018.
Concilium Search recently secured a seven-figure funding package from Lloyds Commercial Banking to grow its international base to expand its international footprint with plans to almost double its turnover from around £11million to over £19m within 12 months.
Martin Badoo, Head of Life Sciences Contracts at Concilium Search, said:
“The demand for skilled contractors and consultants for either high-level interim cover or project-based support is ever increasing in the life sciences sector.
“Our life sciences contract book has grown by 250 per cent year on year which has led us to recruiting more staff ourselves for our UK and USA offices which is very positive news for the industry as a whole. The position we see most demand for varies from client to client. We have seen a lot of growth generated from repeat business, combined with new business which has been driven out of our London and New York offices.”
Mr Badoo said Concilium Search had not experienced any disruption to its business by the uncertainty surrounding Brexit which is predicted to impact the pharmaceutical industry if the UK leaves the European Union without a deal.
“There is naturally some uncertainty within the industry due to Brexit, but we are still placing candidates, and experiencing growth in terms of our life sciences client base. We believe people will still want to work in the UK and UK candidates will still seek work contracts in Europe, even if we leave with a no-deal outcome.”